From the Journals

Bariatric surgery gives 10-year cure for some advanced diabetes


 

First 2 years after surgery is key

“We also learnt that patients who do not go into remission after 2 years are very unlikely to ever do so,” Dr. Miras and Dr. le Roux observed, which “might help us to intensify modern and potent glucose-lowering therapies like SGLT2 inhibitors and GLP-1 receptor agonists earlier after metabolic surgery.”

Ten of 19 patients (53%) in the biliopancreatic diversion group and 10 of 15 patients (67%) in the Roux-en-Y gastric bypass group who had diabetes remission at 2 years had a diabetes relapse, but at 10 years, they all had adequate glycemic control (mean A1c 6.7%), despite drastically reduced use of diabetes medications.

The two patients who crossed over to surgery from the medical therapy group had postoperative diabetes remission, which was maintained at 10 years in one patient.

Better risk-to-benefit ratio with Roux-en-y gastric bypass

No patient in the medical therapy group had a serious adverse event, but one patient in each surgery group had deep vein thrombosis or pulmonary embolism, and one patient in the biliopancreatic diversion group had an episode of atrial fibrillation. There were no late surgical complications.

Iron deficiency and mild osteopenia occurred in both surgical groups, but were more common in the biliopancreatic diversion group. And osteoporosis, transient nyctalopia (night blindness) due to vitamin A deficiency, and kidney stones were observed only with biliopancreatic diversion.

This suggests that despite the greater antidiabetic potential of biliopancreatic diversion, Roux-en-Y gastric bypass might have a more favorable risk-to-benefit profile as a standard surgical option for the treatment of type 2 diabetes, Dr. Mingrone and colleagues concluded.

The authors and Dr. Miras have reported no relevant financial relationships. Dr. le Roux has reported receiving funding from the Science Foundation Ireland, the Health Research Board, and the Irish Research Council for type 2 diabetes research, and serves on several advisory boards outside of the scope of the current study.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Biomarker HF risk score envisioned as SGLT2 inhibitor lodestar in diabetes
MDedge Internal Medicine
Further warning on SGLT2 inhibitor use and DKA risk in COVID-19
MDedge Internal Medicine
Low-carb diets boost diabetes remission rates, at least short term
MDedge Internal Medicine
Widespread liver disease missed in patients with T2D
MDedge Internal Medicine
Monoclonal antibody drops fat, ups muscle in obesity, diabetes
MDedge Internal Medicine
Can ‘big’ be healthy? Yes – and no
MDedge Internal Medicine
Protecting patients with diabetes from impact of COVID-19
MDedge Internal Medicine
Incidence of autoimmune hepatitis may be rising
MDedge Internal Medicine
Gestational diabetes carries CVD risk years later
MDedge Internal Medicine
Plant-based or keto diet? Novel study yields surprising results
MDedge Internal Medicine